Combination of Fecal Microbiota and Fidaxomicin
Fidaxomicin is a novel bactericidal macrocyclic antibiotic that was recently approved for the treatment of CDI [7] . It has a high degree of specificity against C. difficile and has little effect on the composition of the gut microbiota regarding its major phylogenetic clusters.
Studies on the combination of fecal microbiota transplantation and fidaxomicin therapy in the treatment of severe C. difficile colitis are lacking. Hence, we describe the use of a combination of fidaxomicin with FMT in severe CDI.
Case Report
A 76-year-old female patient with a history of chronic recurrent diverticulitis was admitted for surgical treatment of acute diverticulitis. Perioperatively, the patient was treated with cefuroxime 1.5 g/day. The postoperative course was complicated by small bowel-ileus due to mesenteric ischemia. The patient was treated with 2 relaparotomies followed by the introduction of broad spectrum antibiotics (piperacillin-tazobactam 3 × 4.5 g/day). The patient's clinical condition deteriorated and she developed fever and acute diarrhea (>15/day). Her C-reactive protein (CRP; 310 mg/L) and leucocyte counts (24 × 10 9 /L) were markedly increased. A fecal sample was positive for cytotoxin-B producing C. difficile by culture and cytotoxin assay. Colonoscopy demonstrated a severe colitis with multiple pseudomembranes ( Fig. 1 ). Antibiotic therapy with metronidazole and vancomycin was subsequently initiated. Despite these measures, the clinical condition of the patient further deteriorated. She was transferred to the intensive care unit and required mechanical ventilation and catecholamines.
Due to the failure of antibiotic therapy, the decision was taken to perform FMT via colonoscopy. A total of 500 mL of diluted fecal solution from a healthy donor was applied at the cecum and colon ascendens. Within 72 h after FMT, a significant improvement of the inflammatory parameters was observed ( Fig. 2 ) . Because the colitis was not fully resolved, increased CRP (113 mg/L) and the presence of prognostically unfavorable clinical parameters (advanced age, pseudomembranes, fever, increased creatinine to 160 μmol/L) raised concerns about the efficacy of the FMT. Hence, fidaxomicin was introduced at a dose of 2× 200 mg per os (p.o.) 7 days after FMT. Within the next 3 weeks we observed a complete clinical recovery and the stool specimens were negative for CDI. A colonoscopy performed 6 months later showed no pathologic findings in the colon. During the 14-month follow-up, no recurrence of C. difficile infection was observed.
Discussion
In this case, the combination of FMT and fidaxomicin was an efficacious therapy in a patient with severe and complicated CDI. The cause of the disease was antibiotic therapy due to postoperative complications and the patient's advanced age. Conventional therapy consisting of vancomycin and metronidazole failed to heal the CDI. The combination therapy of FMT and fidaxomicin led to the complete healing of CDI colitis and prevented the recurrence of the disease in 14 months of follow-up.
According to previous studies, the presence of severe CDI is associated with the increased risk of failure of FMT therapy [8] . Therefore, the strategy to restore the intestinal microbiota by FMT in combination with fidaxomicin could represent an effective treatment modality in patients with severe CDI. However, the data on the use of this method in fulminant C. difficile colitis are limited. Recently, a successful treatment with fecal microbiota transplantation in patients with C. difficile -induced toxic megacolon was reported [9] . In addition, a small report indicates that the combination of FMT with antibiotic therapy with fidaxomicin could represent an important therapeutic option in patients with severe C. difficile colitis [10] .
Conclusion
In the present case, severe CDI colitis was successfully treated with the combination of FMT and fidaxomicin.
